JPMorgan Raises Eli Lilly Price Target to $1,400 on Mounjaro’s Obesity and Pediatric Momentum
Health Canada has approved Mounjaro for children with type 2 diabetes.
/ 185 items
#XY Analyst Up/Down↓
Benchmark Upgrades AbCellera to Buy with $11 Target on Major Jazz Pharmaceuticals Partnership
AbCellera gets a boost after Jazz deal brings upfront cash and future growth potential through cancer antibody programs and milestones.
Kyntra Bio Scores First Analyst Coverage: Oppenheimer Initiates Outperform with $35 Target
Kyntra Bio gains analyst support as its cancer drugs advance, with key Phase 2 data expected to drive future growth.
TD Cowen Boosts TransMedics Price Target to $120 on Strong Transplant Growth
Accelerating U.S. heart, liver & lung transplants plus strong flight data signal major growth ahead.
Replimune Stock Gets BMO Upgrade to Outperform as FDA De-Risks RP1 Approval
PDUFA date set for August 2, 2026.
Prime Medicine Gets Analyst Upgrade to Buy as First In Vivo Prime Editing Trial Moves Forward
H.C. Wainwright cites New Zealand clearance for PM577a — the first in vivo Prime Editing clinical trial for Wilson’s disease.